8-K: TriSalus Life Sciences Completes Preferred Stock Exchange Offer, Amends Governance

TriSalus Life Sciences successfully completed its exchange offer and consent solicitation for its Series A Convertible Preferred Stock, with 98.82% of shares tendered, simplifying its capital structure.

Summary

• TriSalus Life Sciences commenced an offer to exchange its Series A Convertible Preferred Stock for Common Stock and solicited consents to amend the Certificate of Designations.
• The exchange offer allowed holders of Preferred Stock to receive a number of Common Stock shares equal to the quotient of (i) the sum of the Liquidation Preference and Accrued Dividends (accrued through August 10, 2027) divided by (ii) $4.00.
• The Offer and Consent Solicitation expired on July 23, 2025.
• Approximately 98.82% (3,551,502 shares) of the outstanding Preferred Stock was validly tendered and not withdrawn.
• The company expects to accept all validly tendered Preferred Stock for exchange and settlement on or before August 1, 2025.
• The requisite approval for the Preferred Stock Amendment was received, satisfying the Consent Threshold (majority of outstanding shares, with approximately 55% pre-agreed).
• On July 24, 2025, the company filed the Preferred Stock Amendment with the Secretary of State of the State of Delaware.
• The Preferred Stock Amendment permits the company to require conversion of all outstanding Preferred Stock into Common Stock based on the sum of Liquidation Preference and Accrued Dividends (through closing of the Offer) divided by the amended Conversion Price.

Sentiment

Score: 8

Explanation: The successful completion of the exchange offer with a very high participation rate (98.82%) and the subsequent amendment of the Certificate of Designations are significant positive steps for simplifying the company's capital structure and gaining more control over its preferred stock. This reduces complexity and potential future obligations related to preferred dividends and liquidation preferences, which is generally viewed favorably by investors.

Positives

• Achieved a very high participation rate of 98.82% in the exchange offer, significantly exceeding the 55% consent threshold.
• Successfully amended the Certificate of Designations, simplifying the company's capital structure.
• The company now has a 'Call Option' to convert any remaining outstanding Preferred Stock into Common Stock, providing greater control over its equity structure.

Negatives

• The exchange offer terms, specifically the $4.00 denominator for the exchange value, and the amended Conversion Price of $5.277 (down from an initial $10.00), may have resulted in less favorable conversion terms for some preferred shareholders compared to prior expectations or original terms.
• The conversion of preferred stock into common stock will result in dilution for existing common shareholders.

Risks

• Risks related to the company's ability to attract and retain customers and expand customers' use of its products.
• Risks relating to market, financial, political, and legal conditions.
• Uncertainty of projected financial and operating information with respect to the company.
• Risks related to future market adoption of the company's offerings.
• Risks related to the company's marketing and growth strategies.
• Risks related to the company's ability to acquire or invest in businesses, products, or technologies that may complement or expand its products, enhance its technical capabilities, or otherwise offer growth opportunities.
• The effects of competition on the company's future business.
• General risks discussed in the company's quarterly report on Form 10-Q for the period ended March 31, 2025, and Registration Statement on Form S-4 filed on June 23, 2025.

Future Outlook

The company expects to accept all validly tendered Preferred Stock for exchange and settlement on or before August 1, 2025. The successful completion of the Offer and Consent Solicitation is anticipated to affect the company's capital structure and the dilutive impact of the Preferred Stock, simplifying its equity base.

Management Comments

• Mary Szela, Chief Executive Officer and President, signed the report on behalf of TriSalus Life Sciences, Inc.

Industry Context

TriSalus Life Sciences operates as an oncology-focused medical technology business. It specializes in developing disruptive drug delivery technology aimed at improving therapeutic delivery for solid tumors, addressing critical challenges such as high intratumoral pressure and the immunosuppressive properties of liver and pancreatic tumor immune cells. The company is also exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for various liver and pancreatic indications.

Corporate Governance

Stakeholder Impact

• Shareholders (Preferred Stock): Those who tendered their shares will convert their preferred holdings into common stock, simplifying their investment but potentially at terms different from original expectations. Those who did not tender are now subject to the company's Call Option, which can force conversion.
• Shareholders (Common Stock): Will experience dilution due to the issuance of new common shares from the conversion of preferred stock.
• Company: Benefits from a simplified and more streamlined capital structure, reduced administrative complexity associated with preferred stock, and enhanced control over its equity base through the new Call Option.

Next Steps

• Acceptance and settlement of all validly tendered Preferred Stock on or before August 1, 2025.
• The company may exercise its newly acquired Call Option to convert any remaining outstanding Preferred Stock into Common Stock.

Key Dates

Recommendation

The successful completion of the exchange offer and the amendment of the Certificate of Designations are positive steps for TriSalus Life Sciences, simplifying its capital structure and providing greater control over its preferred stock. This reduces future financial complexity and potential obligations. However, the conversion of preferred stock into common stock will result in dilution for existing common shareholders. While the capital structure simplification is a long-term positive, the immediate impact of dilution and the specific terms of the exchange (e.g., the $4.00 denominator for exchange value and the $5.277 conversion price) require further analysis in the context of the company's overall financial health and market valuation. Without more comprehensive financial data or operational updates, a 'hold' recommendation is prudent, acknowledging the positive structural change while noting the dilutive effect.

Keywords

TriSalus Life Sciences, TLSI, Preferred Stock, Common Stock, Exchange Offer, Consent Solicitation, Capital Structure, Corporate Governance, SEC Filing, 8-K, Medical Technology, Oncology, Nasdaq